PMID- 12528764
OWN - NLM
STAT- MEDLINE
DCOM- 20030227
LR  - 20190906
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 252
IP  - 5
DP  - 2002 Nov
TI  - Homocysteine, malondialdehyde and endothelial markers in dialysis patients during 
      low-dose folinic acid therapy.
PG  - 456-64
AB  - OBJECTIVES: Haemodialysis patients have elevated levels of the atherogenic amino 
      acid homocysteine. We wanted to assess the effects of small doses of intravenous 
      folinic acid (the active form of folic acid) on some biochemical risk factors of 
      cardiovascular disease. DESIGN: Longitudinal and open intervention study. 
      SETTING: Two dialysis units in the County of Rogaland. SUBJECTS: All patients on 
      maintenance haemodialysis were invited, and 32 of 35 patients gave their informed 
      consent. INTERVENTIONS: After each dialysis session, the patients were given 1.0 
      mg of folinic acid intravenously thrice a week for a period of 3 months. Prior to 
      and during the study, all patients were on maintenance supplementation with small 
      doses of vitamins B1, B2, B3, B5, B6 and B12. MAIN OUTCOME MEASURES: Changes in 
      the levels of (i) plasma total homocysteine (p-tHcy) and folate, (ii) circulating 
      endothelium related proteins--markers of endothelial activation and (iii) serum 
      malondialdehyde (S-MDA)--a marker of oxidative stress and lipid peroxidation. 
      RESULTS: The p-tHcy levels were reduced by 37% (P < 0.0001), whilst the serum and 
      erythrocyte folate levels increased by 95 and 104%, respectively (P < 0.0001 for 
      both). The circulating levels of endothelium related cellular adhesion molecules 
      and haemostatic factors remained high and unchanged, except the thrombomodulin 
      (TM) levels increased (P = 0.0004). The high levels of S-MDA were reduced by 26% 
      (P = 0.003). CONCLUSIONS: Low doses of folinic acid given intravenously to 
      dialysis patients reduced their levels of p-tHcy and S-MDA and thus improved 
      their cardiovascular risk profile. The concurrent increment in TM levels was 
      unexpected and of unknown clinical significance.
FAU - Apeland, T
AU  - Apeland T
AD  - Renal Unit, Department of Medicine, Rogaland Central Hospital, Stavanger, Norway. 
      apeland@online.no
FAU - Mansoor, M A
AU  - Mansoor MA
FAU - Seljeflot, I
AU  - Seljeflot I
FAU - Bronstad, I
AU  - Bronstad I
FAU - Goransson, L
AU  - Goransson L
FAU - Strandjord, R E
AU  - Strandjord RE
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Hemoglobins)
RN  - 0 (Serum Albumin)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - AYI8EX34EU (Creatinine)
RN  - Q573I9DVLP (Leucovorin)
SB  - IM
MH  - Creatinine/blood
MH  - Endothelium, Vascular
MH  - Female
MH  - Hemoglobins/analysis
MH  - Homocysteine/*blood
MH  - Humans
MH  - Infusions, Intravenous
MH  - Kidney Failure, Chronic/*blood/therapy
MH  - Leucovorin/*administration & dosage
MH  - Longitudinal Studies
MH  - Male
MH  - Malondialdehyde/*blood
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Renal Dialysis
MH  - Serum Albumin/analysis
EDAT- 2003/01/17 04:00
MHDA- 2003/02/28 04:00
CRDT- 2003/01/17 04:00
PHST- 2003/01/17 04:00 [pubmed]
PHST- 2003/02/28 04:00 [medline]
PHST- 2003/01/17 04:00 [entrez]
AID - 10.1046/j.1365-2796.2002.01056.x [doi]
PST - ppublish
SO  - J Intern Med. 2002 Nov;252(5):456-64. doi: 10.1046/j.1365-2796.2002.01056.x.